Adoptive transfer of antigen-specific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants

Immunologic Research

Volumn 38, Issue 1-3, 2007, Pages 237-250

  O'Reilly, Richard J ^a   Doubrovina, Ekaterina ^a   Trivedi, Deepa ^a   Hasan, Aisha ^a   Kollen, Wouter ^a   Koehne, Guenther ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adoptive immunotherapy; Transplant associated infection

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ACUTE LYMPHOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN SPECIFICITY; CONFERENCE PAPER; CYTOREDUCTIVE SURGERY; HUMAN; IMMUNOTHERAPY; IN VITRO STUDY; MORTALITY; PREVENTION AND CONTROL; PREVENTION STUDY; PRIORITY JOURNAL; RECURRENCE RISK; RISK FACTOR; T CELL DEPLETION; T LYMPHOCYTE; VIRUS INFECTION;

ADOPTIVE TRANSFER; ADULT; CHILD; CYTOMEGALOVIRUS INFECTIONS; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA ANTIGENS; HUMANS; IMMUNOTHERAPY; MALE; T-LYMPHOCYTES; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 35348866123     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12026-007-0059-2     Document Type: Conference Paper

References (60)

1. Gatti RA, Meuwissen HJ, Allen HD, Hong R, Good RA. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 1968;2:1366-69.
2. Antoine C, Muller S, Cant A, Cavazzana-Calvo, et al. Long-term survival and transplantation of hematopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet 2003;361:553-60.
3. Krivit W. Allogenic stem cell transplantation for the treatment of lysosomal and peroxisomal metabolic diseases. Springer Semin Immunopathol 2004;26:119-32.
4. Lucarelli G, Andreani M, Angelucci E. The cure of thalassemia by bone marrow transplantation. Blood Rev 2002;16:81-5.
5. Appelbaum FR. Allogenic hematopoietic stem cell transplantation for acute leukemia. Semin Oncol 1997;24:114-23.
6. Kiehl MG, Kraut L, Schwerdtfeger R, Hertenstein B, et al. Outcome of allogenic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. J Clin Oncol 2004; 22:2816-25.
7. Khouri IF. Reduced-intensity regimens in allogenic stem-cell transplantation for non-hodgkin lymphoma and chronic lymphocytic leukemia. Hematol Am Soc Educ Program 2006;390-7.
8. Dreger P, Brand R, Hansz J, Milligan D, et al. Treatment-related mortality and graft-versus-leukemia activity after allogenic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia 2003;17:841-8.
9. O'Reilly R.J., Dupont B., Pahwa S., Grimes, E et al. Reconstitution in severe combined immunodeficiency by transplantation of marrow from an unrelated donor. N Engl J Med 1977; 297:1311-18.
10. McCullough J, Perkins HA, Hansen J. The National Donor Program with emphasis on the early years. Transfusion 2006; 46:1248-55.
11. Drobyski WR, Klein J, Flomenberg N, Pietryga D, Vesole DH, Margolis DA, Keever-Taylor CA. Superior survival associated with transplantation of matched unrelated versus one-antigen-mismatched unrelated or highly human leukocyte antigen-disparate haploidentical family donor marrow grafts for the treatment of hematologic malignancies: establishing a treatment algorithm for recipients of alternative donor grafts. Blood 2002;99:806-14.
12. Mielcarek M, Martin PJ, Leisenring W, Flowers MED, et al. Graft-versus-host disease after nonmeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003;102:756-62.
13. Flomenberg N, Baxter-Lowe LA, Confer D, Fernandez-Vina M, et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004;104:1923-30.
14. Reisner Y, Kapoor N, Kirkpatrick D, Pollack MS, Dupont B, Chaganti RSK, Good RA, O'Reilly RJ. Transplantation for acute leukemia with HLA-A & B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells. Lancet 1981;2:327-31.
15. Reisner Y, Kapoor N, Kirkpatrick D, Pollack MS, Cunningham-Rundles S, Dupont B, Hodes MZ, Good RA, O'Reilly RJ. Transplantation for severe combined immunodeficiency with HLA-A, B, D, Dr incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood 1983;61:341-8.
16. Small T, Friedrich W, O'Reilly R. Hematopoietic cell transplantation for immunodeficiency disease. In: Blume KB, Forman SJ, Appelbaum FR, editors. Thomas' hematopoietic cell transplantation. 3rd ed. Malden, Massachusetts: Blackwell Science, Chapter 105. 2003.
17. Friedrich W, Goldmann SF, Vetter U, et al. Immunoreconstitution in severe combined immunodeficiency after transplantation of HLA-haploidentical, T-cell depleted bone marrow. Lancet 1984;1:761-64.
18. Buckley RH, Schiff SE, Schiff RI, et al. Hematopoietic stem cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 1999;340:508-16.
19. Young JW, Papadopoulos E, Cunningham I, Castro-Malaspina H, et al. T cell-depleted allogeneic bone marrow transplantation in adults with acute nonlymphocytic leukemia in first remission. Blood 1992;79:3380-87.
20. Papadopoulos EB, Carabasi MH, Castro-Malaspina H, Childs BH, Mackinnon S, Boulad F, Gillio F, Gillio AP, Kernan NA, Small TN, Szabolcs P, Taylor J, Yahalom J, Collins NH, Bleau SA, Black PM, Heller G, O'Reilly RJ, Young JW. T cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: Freedom from relapse in the absence of graft-vs-host disease. Blood 1998;91(3):1083-90.
21. Jakubowski A, Papadopoulos E, Kernan NA, Boulad F, Castro-Malaspina HR, Collins N, Hsu K, Perales M, Small T, van den Brink M, Young J, O'Reilly RJ. Results of T cell depleted (TCD) allogenic hematopoietic stem cell transplantation (AlloHSCT) from HLA matched (HLA-M) or partially mismatched (HLA-MM) unrelated donors (URD) in patients with hematologic malignancies: sustained engraftment and low incidence of graft vs. host disease (GvHD). Blood 2006;3133:894a.
22. Small TN, Papadopoulos E, Boulad F, Black P, Castro-Malaspina H, Childs B, Collins N, George D, Gillio A, Heller G, Jakubowski A, Kernan NA, MacKinnon S, Szabolcs P, Young J, O'Reilly RJ. Comparison of immune reconstitution following unrelated and related T-cell depleted bone marrow transplantation: Effect of patient age and donor leukocyte infusions. Blood 1999;93:467-80.
23. Almyroudis ND, Jakubowski A, Jaffe D, Sepkowitz K, Pamer E, O'Reilly RJ, Papnicolaou GA. Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation. Trans Infect Dis 2007; (in Press).
24. Martin PJ, Shulman HM, Schubach WH, Hansen JA, Fefer A, Miller G, Thomas ED. Fatal Epstein-Barr-virus-associated proliferation of donor B cells after treatment of acute graft-versus-host disease with a murine anti-T-cell antibody. Ann Intern Med 1984;101:310-5.
25. Lucas KG, Small TN, Heller G, Dupont B, O'Reilly RJ. The development of cellular immunity to Epstein-Barr virus following allogeneic bone marrow transplantation. Blood 1996;87:2594-603.
26. Curtis RE, Travis LB, Rowlings PA, Socie G, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: A multi-institutional study. Blood 1999;94:2208-16.
27. Tan LC, Gudgeon N, Annels NE, Hanasasuta P, et al. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J Immunol 1999;162:1827-35.
28. Svedmyr E, Jondal M. Cytotxic effector cells specific for B cell lines transformed virus are present in patients with infectious mononucleosis. Proc Natl Acad Sci USA 1975;72:1622-26.
29. Rickinson AB, Crawford D, Epstein MA. Inhibition of the in vitro outgrowth of Epstein-Barr virus-transformed lymphocytes by thymus-dependent lymphocytes from infectious mononucleosis patients. Clin Exp Immunol 1977;28:72-9.
30. Purtilo DT, Okano M, Grierson HL. Immune deficiency as a risk factor in Epstein-Barr virus-induced malignant diseases. Environ Health Perspect 1990;88:225-30.
31. Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, Castro-Malaspina H, Childs BH, Gillio AP, Small TN, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994;330:1185-91.
32. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998;92:1549-55.
33. Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996;2:551-55.
34. Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L, Ponzoni M, Rossini S, Mavilio F, Traversari C, Bordignon C. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997;276:1719-24.
35. Haque T, Wilkie GM, Taylor C, Amlot PL, Murad P, Iley A, Dombagoda D, Britton KM, Swerdlow AJ, Crawford DH. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 2002;360:436-42.
36. Savoldo B, Huls MH, Liu Z, et al. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood 2002;100:4059-66.
37. Heslop HE, Brenner MK, Rooney CM. Donor T cells to treat EBV-associated lymphoma. N Engl J Med 1994;331:679-80.
38. Gottschalk S, Ng CY, Perez M, Smith C, Sample C, Brenner M, Heslop HE, Rooney CM. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood 2001;97:835-43.
39. Boeckh M, Leisenring E, Riddell S, Bowden RA, Huang M, Myerson D, et al. Late cytomegalovirus disease and mortality in recipients of allogenic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003;101:407-14.
40. Ljungman P, Aschan J, Lewensohn-Fuchs I, et al. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. Transplantation 1998;66:1330-34.
41. Riddell S, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by adoptive transfer of T-cell clones. Science 1992;257:238-41.
42. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;333:1038-44.
43. Peggs K, Verfuerth S, Mackinnon S. Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: a novel culture system free of live CMV virions. Blood 2001;97:994-1000.
44. Peggs KS, MacKinnon S. Augmentation of virus-specific immunity after hematopoietic stem cell transplantation by adoptive T-cell therapy. Human Immunol 2004;65:550-7.
45. Rauser G, Einsele H, Sinzger C, Wernet D, Kuntz G, Assenmacher M, Campbell J, Topp MS. Rapid generation of combined CMV-specific CD4+ and CD8+ T-ell lines for adoptive transfer into recipients of allogeneic stem cell transplants. Blood 2004;103:3565-72.
46. Cobbold M, Khan N, Pourgheysari B, Tauro S, et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. JEM 2005;202:379-86.
47. Wills MR, Carmichael AJ, Mynard K, Jin X, et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T cell receptor usage of pp65-specific CTL. J Virol 1996;70:7569-79.
48. Elkington R, Walker S, Crough T, Menzies M, et al. Ex vivo profiling of CD8+ T-cell responses to human cytomegalovirus reveals broad and multispecific reactivies in healthy virus carriers. J Virol 2003;77:5226-40.
49. Kern F, Faulhaber N, Frommel C, Khatamzas E, Prosch S, et al. Analysis of CD8 T cell reactitivy to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur J Immunol 2000;30:1676-82.
50. Trivedi D, Williams R, O'Reilly R, Koehne G. Generation of cytomegalovirus (CMV)-specific T-lymphocytes using protein-spanning pools of PP65-derived over-lapping pentadecapeptides for adoptive immunotherapy. Blood 2005;105(7):2793-801.
51. Lacey SF, Villacres MC, La Rosa C, Wang Z, Longmate J, Martinez J, Brewer JC, Mekhoubad S, Maas R, Leedom JM, Forman SJ, Zaia JA, Diamond DJ. Relative dominance of HLA-B*07 restricted CD8+ T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles. Hum Immunol 2003;64:440-52.
52. Small TN, Papadopoulos E, Boulad F, Black P, Castro-Malaspina H, et al. Comparison of immune reconstitution following unrelated and related T-cell depleted bone marrow transplantation: Effect of patient age and donor leukocyte infusions. Blood 1999;93:467-80.
53. Lewin SR, Heller G, Ahang L, Rodrigues BS, Skulsky E, vanden Brink MRM, Small TN, Kernan NA, O'Reilly RJ, Ho DD, Young JW. Direct evidence for new T cell generation by patients after either T cell-depleted or unmodified allogeneic hematopoietic stem cell transplants. Blood 2002;100:2235-42.
54. Pelte C, Cherepnev G, Wang Y, Schoenemann C, Volk H, Kern F. Random screening of proteins of HLA-A*0201-binding nine-amino acid peptides is not sufficient for identifying CD8 T cell epitopes recognized in the context of HLA-A*0201. J Immunol 2004;172:6783-89.
55. Latouche JB, Sadelain M. Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells. Nature Biotechnology 2000;18:405-9.
56. Papanicolaou GA, Latouche JB, Tan C, Dupont J, Stiles J, Pamer EG, Sadelain M. Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele. Blood 2003;102:2498-505.
57. Hasan A, Kollen W, Trivedi, Selvakumar A, Sadelain M, O'Reilly RJ. A panel of artificial antigen presenting cells (AAPC) permits immediate sensitization and rapid generation of virus-specific T cells of desired HLA restriction for adoptive immunotherapy. Blood 2006;3268:933a.
58. Trivedi D, Kollen W, Barnett L, Sadelain M, O'Reilly RJ. Artificial antigen-presenting cells permit selective In Vitro generation of CMV-Specific T cells of desired HLA allelic restriction for adoptive immunotherapy in recipients of HLA disparate allografts. Blood 2005;106:377a.
59. Aversa F, Terenzi A, Tabilio A, Falzetti F, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005;23:3447-54.
60. Perruccio K, Tosti A, Burchielli E, Topini F, et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 2005;106:4397-406.